Altered elimination of antipyrine in patients with acute viral hepatitis
- PMID: 1278717
- PMCID: PMC1411129
- DOI: 10.1136/gut.17.5.341
Altered elimination of antipyrine in patients with acute viral hepatitis
Abstract
The plasma half-life and clearance of antipyrine was investigated in patients during the acute phase and again during the recovery phase of viral hepatitis. Each patient served as his own control, thereby eliminating genetic factors and minimising environmental factors that cause large interindividual variations in antipyrine elimination rates. Liver function tests, antipyrine, half-life, plasma clearance, and the apparent volume of distribution were determined in the acute and recovery period. It was found that the appaarent volume of distribution of antipyrine did not change in five of six patients as they recovered. Five of the six patients showed prolonged plasma half-lives and decreased plasma clearance of the drug at the time of acute illness and these parameters reached normal values during recovery. The plasma half-life and clearance of the drug did not correlate with biochemical indices of liver function in the recovery phase. This demonstration supports the concept that drug metabolism is frequently impaired in liver disease.
Similar articles
-
Impairment of hepatic drug metabolism in patients with acute viral hepatitis.Eur J Drug Metab Pharmacokinet. 1982 Oct-Dec;7(4):255-8. doi: 10.1007/BF03189627. Eur J Drug Metab Pharmacokinet. 1982. PMID: 7166177
-
Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone.Biomedicine. 1979 Sep;31(5):135-8. Biomedicine. 1979. PMID: 508896
-
Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance.Clin Pharmacol Ther. 1975 Apr;17(4):447-57. doi: 10.1002/cpt1975174447. Clin Pharmacol Ther. 1975. PMID: 1122686
-
The effect of fenfluramine on disposition and rate of antipyrine elimination.Pharmacology. 1975;13(1):12-9. doi: 10.1159/000136880. Pharmacology. 1975. PMID: 1153500
-
Factors influencing antipyrine elimination.Br J Clin Pharmacol. 1977 Jun;4(3):261-5. doi: 10.1111/j.1365-2125.1977.tb00710.x. Br J Clin Pharmacol. 1977. PMID: 332216 Free PMC article. Review. No abstract available.
Cited by
-
Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.Clin Pharmacokinet. 1991 Jan;20(1):50-65. doi: 10.2165/00003088-199120010-00004. Clin Pharmacokinet. 1991. PMID: 2029802 Review.
-
An evaluation of urinary D-glucaric acid excretion during acute hepatitis in man.Am J Dig Dis. 1978 Jan;23(1):18-22. doi: 10.1007/BF01072570. Am J Dig Dis. 1978. PMID: 619622 No abstract available.
-
Impairment of hepatic drug metabolism in patients with acute viral hepatitis.Eur J Drug Metab Pharmacokinet. 1982 Oct-Dec;7(4):255-8. doi: 10.1007/BF03189627. Eur J Drug Metab Pharmacokinet. 1982. PMID: 7166177
-
Drug prescribing in hepatobiliary disease.Drugs. 1979 Mar;17(3):198-212. doi: 10.2165/00003495-197917030-00005. Drugs. 1979. PMID: 378647 Review.
-
Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients.Antimicrob Agents Chemother. 1992 Oct;36(10):2245-52. doi: 10.1128/AAC.36.10.2245. Antimicrob Agents Chemother. 1992. PMID: 1444306 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources